GlassScriptPhysician profile
Jason E Zinn
NPI 1457350308
$10,102.22
in general payments reported to CMS, 2019-2025
46 companies · $2,286 in 2025
The $2,286 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,753 · 2022: $1,851 · 2023: $2,221 · 2024: $1,990 · 2025: $2,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,497.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,188.09 | 2021-2025 | |
| Novo Nordisk INC | $1,095.65 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $753.81 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $709.39 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $697.48 | 2021-2025 | |
| Lilly USA, LLC | $602.01 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $513.31 | 2021-2025 | Evenity, Prolia, Otezla |
| Teva Pharmaceuticals USA, INC. | $361.11 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.20 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $265.73 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.93 | 2021-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $253.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $230.80 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $162.73 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $141.09 | 2021-2025 | Rexulti |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Zinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.